Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Capital Expenditures (2016 - 2024)

Historic Capital Expenditures for Ascendis Pharma A (ASND) over the last 13 years, with Q3 2024 value amounting to -$512868.5.

  • Ascendis Pharma A's Capital Expenditures rose 5172.84% to -$512868.5 in Q3 2024 from the same period last year, while for Sep 2024 it was -$1.0 million, marking a year-over-year increase of 8432.71%. This contributed to the annual value of -$2.6 million for FY2023, which is 8222.58% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Capital Expenditures of -$512868.5 as of Q3 2024, which was up 5172.84% from -$368295.6 recorded in Q2 2024.
  • Over the past 5 years, Ascendis Pharma A's Capital Expenditures peaked at $48.7 million during Q4 2021, and registered a low of -$13.3 million during Q3 2021.
  • Moreover, its 5-year median value for Capital Expenditures was -$3.2 million (2022), whereas its average is $1.7 million.
  • Data for Ascendis Pharma A's Capital Expenditures shows a peak YoY increase of 31562.32% (in 2020) and a maximum YoY decrease of 134486.11% (in 2020) over the last 5 years.
  • Ascendis Pharma A's Capital Expenditures (Quarter) stood at $42.3 million in 2020, then grew by 15.31% to $48.7 million in 2021, then crashed by 107.92% to -$3.9 million in 2022, then skyrocketed by 101.76% to $67784.2 in 2023, then plummeted by 856.62% to -$512868.5 in 2024.
  • Its Capital Expenditures was -$512868.5 in Q3 2024, compared to -$368295.6 in Q2 2024 and -$216186.0 in Q1 2024.